technologynetworks.com
Cure8 news brief
Why This Matters
The study pinpoints a genetic cause (BIRC3 variants) that disrupts a TNF/RIPK1 immune pathway linked to Crohn’s disease, suggesting a targetable mechanism. That could help doctors match patients to treatments and guide development of more precise therapies.
Who Should Pay Attention
Patients with Crohn’s disease (including those with early-onset or familial disease), caregivers, pediatric and adult IBD clinicians, geneticists, and researchers working on IBD genetics, immune pathways, or targeted therapies.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
Researchers at SickKids report identifying variants in the BIRC3 gene that disrupt RIPK1/TNF signaling and were found in 14 Crohn’s patients from 10 families. The team used genetics, RNA sequencing, proteomics and animal models (mouse and zebrafish) and published the findings in Gastroenterology.
They suggest the pathway may be druggable and could help predict anti-TNF response; a RIPK1 inhibitor is already in clinical trials. What this means: this study identifies a new monogenic cause of Crohn’s linked to BIRC3 and maps how those variants cause inflammation through a RIPK1-related TNF pathway.
The authors propose that the pathway could be targeted for precision treatments and that some adult-onset or familial Crohn’s cases might have similar single-gene drivers.
Practical takeaway: this is a genetics-driven discovery that may lead to more targeted options and better matching of therapies in the future, but it describes a rare genetic cause and research steps (models, pathway mapping) rather than an immediate change in clinical care.
If you’re interested in more detail: the published paper in Gastroenterology is the primary source for methods, patient numbers, and specific data supporting these conclusions.
Keep In Mind
The report is based on a published Gastroenterology study combining human genetics and lab models; the identified cause appears rare but may illuminate a common pathway. Findings point toward future precision applications, not immediate clinical practice changes. A RIPK1 inhibitor is in trials, but patient use would depend on further clinical evidence and approvals.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical study
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationtechnologynetworks.com
Indexed viaBing News
Source typeResearch news
PublishedJun 25, 2026, 2:53 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
SickKids-led research uncovers new genetic cause of Crohn's disease | EurekAlert!
Scientists found BIRC3 gene changes that cause Crohn’s in some patients and showed those changes drive inflammation through the RIPK1/TNF pathway. That suggests a new, druggable pathway and may help predict who benefits...
Discovery of BIRC3 gene variants in Crohn's disease yields a druggable pathway
This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to...
Why anti-TNF drugs don't work for some kids with Crohn's disease - Medical Xpress
This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.